Den godkendte anvendelse i Nederlandene var en startdosis på 5 mg hos patienter med prædisponeringsfaktorer for myopati og 10 mg som anbefalet startdosis for patienter uden disse prædisponeringsfaktorer.
The approved use in The Netherlands was a 5 mg start dose for patients with predisposing factors to myopathy, and 10 mg as the recommended start dose for patients without these predisposing factors.